首页> 外文OA文献 >Imaging chemokine receptor dimerization with firefly luciferase complementation
【2h】

Imaging chemokine receptor dimerization with firefly luciferase complementation

机译:萤火虫荧光素酶互补成像趋化因子受体二聚化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Seven-transmembrane (G-protein coupled) receptors are key regulators of normal physiology and a large number of diseases, and this family of receptors is the target for almost half of all drugs. Cell culture models suggest that homodimerization and heterodimerization of 7-transmembrane receptors regulate processes including specificity of ligand binding and activation of downstream signaling pathways, making receptor dimerization a critical determinant of receptor biology and a promising new therapeutic target. To monitor receptor dimerization in cell-based assays and living animals, we developed a protein fragment complementation assay based on firefly luciferase to investigate dimerization of chemokine receptors CXCR4 and CXCR7, two 7-transmembrane receptors with central functions in normal development, cancer, and other diseases. Treatment with chemokine ligands and pharmacologic agents produced time- and dose-dependent changes in reporter signal. Chemokines regulated reporter bioluminescence for CXCR4 or CXCR7 homodimers without affecting signals from receptor heterodimers. In a tumor xenograft model of breast cancer, we used bioluminescence imaging to measure changes in receptor homodimerization in response to pharmacologic agents. This technology should be valuable for analyzing function and therapeutic modulation of receptor dimerization in intact cells and living mice.—Luker, K. E., Gupta, M., Luker, G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation.
机译:七跨膜(G蛋白偶联)受体是正常生理和许多疾病的关键调节剂,该受体家族是几乎所有药物的靶标。细胞培养模型表明7跨膜受体的同二聚化和异二聚化调节过程包括配体结合的特异性和下游信号通路的激活,使受体二聚化成为受体生物学的关键决定因素和有希望的新治疗靶点。为了在基于细胞的测定法和活体动物中监测受体二聚化,我们开发了一种基于萤火虫荧光素酶的蛋白质片段互补测定法,以研究趋化因子受体CXCR4和CXCR7(在正常发育,癌症和其他疾病中具有中心功能的两个7跨膜受体)的二聚化。疾病。用趋化因子配体和药物治疗可以使报告信号产生时间和剂量依赖性的变化。趋化因子调节CXCR4或CXCR7同型二聚体的报告分子生物发光,而不影响受体异二聚体的信号。在乳腺癌的肿瘤异种移植模型中,我们使用生物发光成像来测量响应药物的受体均二聚化的变化。这项技术对于分析完整细胞和活小鼠中受体二聚化的功能和治疗调节具有重要价值。— Luker,K. E.,Gupta,M.,Luker,G. D.用萤火虫荧光素酶互补成像趋化因子受体二聚化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号